Danish researchers found patients with poorly controlled type 1 diabetes had a nonsignificant -0.6% decrease in A1C levels from baseline to 12 weeks after adding once-daily liraglutide 1.2 mg to insulin, compared to -0.5% among those with a placebo add-on. The findings based on 40 diabetes patients with a body mass index of 18 to 28 and ages 18 to 70, also showed 90% of those on liraglutide and 65% of those on placebo experienced adverse events, most of which were gastrointestinal. Diabetes Care, Nov. 2015